Tandem Diabetes Completes $287 Million Private Placement

Represented Tandem Diabetes Care (NASDAQ: TNDM) in its private placement offering, consisting of $287.5 million aggregate principal amount of 1.50 percent Convertible Senior Notes due 2025, including $37.5 million principal amount of notes purchased at the election of the purchasers.

Tandem, based in San Diego, California, is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. Among other products, Tandem manufactures and sells the t:slim X2 insulin pump, which is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring and automated insulin delivery.